Phase 2 N=35 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
Niemann-Pick Disease, Type C
Primary: Oxysterol Levels — 28.09; 27.64 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=47 Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Ovarian Cancer
Primary: Number of Participants Who Completed a 4-dose Series of Catumaxomab Infusions (Defined as 10-20-50-150 Micrograms) Within 21 Days — 29 Participants
Phase 2 N=25 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Response Rate (Complete and Partial Response) — 0 participants
Phase 2 N=109 Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Recurrent Melanoma · Stage IV Melanoma
Primary: Response Rate (Complete and Partial) — 5; 3 Percent of participants
Phase 2 N=162 Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
Lung Cancer · Non Small Cell Lung Cancer
Primary: Progression-free Survival — 4.5 Months
Phase 2 N=66 Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome
Hantavirus Infections
Primary: The Proportion of Subjects Who Develop Death, PaO2/FiO2 Ratio Less Than or Equal to 55, Cardiac Index Less Than or Equal to 2.2, Pulseless Electrical Activity…
Phase 2 N=23 Umbilical Cord Blood Infusion to Treat Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Children With T1D Underwent a Single Autologous UCB Transfusion — -0.6 ng /ml /120 min — p=>0.05
Phase 2 N=37 S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Leukemia
Primary: Number of Patients With Complete Remission — 3 participants
Phase 2 N=10 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
Kidney Transplantation · Kidney Disease
Primary: Number of Acute Rejections in All Enrolled Participants — 1 Rejection Events
Phase 2 N=82 Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: Percentage of Participants With Clinical Benefit — 50.0; 48.7 percentage of participants
Phase 2 N=33 Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
Lymphoma, B-Cell · Lymphoma, Non-Hodgkin
Primary: Phase I Maximum Tolerated Dose — 6 mg/m^2
Phase 2 N=50 Repetitive Transcranial Magnetic Stimulation for "Voices"
Schizophrenia
Primary: Hallucination Change Score (HCS) After 9 Active/Sham rTMS Sessions — 5.85; 8.61 Units on a scale — p=.005
Phase 2 N=130 Levetiracetam XR in Very Heavy Drinkers
Alcoholism
Primary: The Percentage of Subjects With no Heavy Drinking Days During Study Weeks 5 Through 14. — 18.2; 14.1 percentage of subjects
Phase 2 N=20 Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity · Cocaine-Related Disorders
Primary: the Adult ADHD Rating Scale (AARS) (30% Reduction) — 50 percent of participants
Phase 2 N=77 Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…